Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Condition:   Non-Small-Cell Lung Carcinoma Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Pemetrexed;   Dietary Supplement: Folic acid 350-1000 μg;   Dietary Supplement: Vitamin B12 1000 μg;   Drug: Dexamethasone 4 mg;   Drug: Saline solution Sponsor:   Merck Sharp & Dohme Corp. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials